Dostarlimab for treating dMMR or MSI-H primary advanced or recurrent endometrial cancer

Published on 13 Sep 2024
Last Updated on 17 Feb 2025

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Dostarlimab 500 mg concentrate for solution for infusion, in combination with carboplatin and paclitaxel, followed by dostarlimab as monotherapy for untreated mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Treatment with dostarlimab should be stopped at 3 years, or earlier if disease progresses.

Funding status

Dostarlimab 500 mg concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2025.

Clinical indications, subsidy class and MediShield Life claim limits for dostarlimab are provided in the Annex.

Dostarlimab for treating dMMR or MSI-H primary advanced or recurrent endometrial cancer (Updated 17 Feb 2025) [PDF, 223 KB]

PES Dostarlimab for treating primary advanced or recurrent endometrial cancer (Updated 17 Feb 2025) [PDF, 55 KB]